Patents Assigned to Theravalues Corporation
-
Publication number: 20240091173Abstract: To reveal which curcumin preparation, among various existing curcumin preparations, is effective for various symptoms of a common cold. Provided is an agent for relieving common cold symptom which contains, as an active ingredient, a curcumin-containing composition that contains fine particles of curcumin or turmeric pigment, or a mixture containing curcumin or turmeric pigment containing an amorphous thereof and a cellulose derivative.Type: ApplicationFiled: December 6, 2022Publication date: March 21, 2024Applicant: THERAVALUES CORPORATIONInventor: Yoshitaka KUWABARA
-
Patent number: 11911348Abstract: To provide a therapeutic agent for cancer having a higher therapeutic effect. A therapeutic agent for cancer, containing: at least one selected from the group consisting of curcumin and a derivative thereof; and at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody in combination.Type: GrantFiled: October 9, 2020Date of Patent: February 27, 2024Assignee: THERAVALUES CORPORATIONInventors: Yutaka Kawakami, Tomonori Yaguchi, Taeko Hayakawa, Atsushi Imaizumi
-
Patent number: 11672770Abstract: A curcumin-containing composition has improved oral absorbability. An oral ingestion composition contains: (A) solid curcumin containing an amorphous body and/or an analog thereof; and (B) a solid water-soluble polymer which becomes viscous in an aqueous medium having a pH of 5 or more.Type: GrantFiled: February 18, 2019Date of Patent: June 13, 2023Assignee: THERAVALUES CORPORATIONInventors: Yuji Makino, Tsukasa Takahashi
-
Publication number: 20210023025Abstract: To provide a therapeutic agent for cancer having a higher therapeutic effect. A therapeutic agent for cancer, containing: at least one selected from the group consisting of curcumin and a derivative thereof; and at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody in combination.Type: ApplicationFiled: October 9, 2020Publication date: January 28, 2021Applicant: THERAVALUES CORPORATIONInventors: Yutaka KAWAKAMI, Tomonori YAGUCHI, Taeko HAYAKAWA, Atsushi IMAIZUMI
-
Patent number: 10849862Abstract: To provide a therapeutic agent for cancer having a higher therapeutic effect. A therapeutic agent for cancer, containing: at least one selected from the group consisting of curcumin and a derivative thereof; and at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody in combination.Type: GrantFiled: December 24, 2015Date of Patent: December 1, 2020Assignee: THERAVALUES CORPORATIONInventors: Yutaka Kawakami, Tomonori Yaguchi, Taeko Hayakawa, Atsushi Imaizumi
-
Patent number: 10245238Abstract: Provided is a composition for oral intake, which exhibits improved oral absorbability of curcumin and/or an analog thereof and can be produced conveniently and inexpensively. A complex of curcumin and/or an analog thereof and a water-soluble cellulose derivative is disclosed.Type: GrantFiled: May 14, 2015Date of Patent: April 2, 2019Assignees: THERAVALUES CORPORATIONInventors: Hirofumi Takeuchi, Kohei Tahara, Atsushi Imaizumi, Tsukasa Takahashi, Takato Matsui, Hitomi Ozawa
-
Publication number: 20170239194Abstract: Provided is a composition for oral intake, which exhibits improved oral absorbability of curcumin and/or an analog thereof and can be produced conveniently and inexpensively. A complex of curcumin and/or an analog thereof and a water-soluble cellulose derivative is disclosed.Type: ApplicationFiled: May 14, 2015Publication date: August 24, 2017Applicants: THERAVALUES CORPORATIONInventors: Hirofumi TAKEUCHI, Kohei TAHARA, Atsushi IMAIZUMI, Tsukasa TAKAHASHI, Takato MATSUI, Hitomi OZAWA
-
Patent number: 9326990Abstract: Provided are a medicine and a food product that suppress a heart disease such as cardiomegaly and heart failure. Specifically provided is an agent for suppressing a heart disease selected from heart failure, cardiac fibrosis, ventricular wall thickening and cardiomegaly, which comprises luteolin or a derivative thereof as an active ingredient.Type: GrantFiled: July 19, 2012Date of Patent: May 3, 2016Assignees: THE UNIVERSITY OF TOKYO, THERAVALUES CORPORATIONInventors: Hiroyuki Morita, Ryozo Nagai, Atsuko Nakayama, Tadashi Hashimoto
-
Publication number: 20140194372Abstract: Provided are a medicine and a food product that suppress a heart disease such as cardiomegaly and heart failure. Specifically provided is an agent for suppressing a heart disease selected from heart failure, cardiac fibrosis, ventricular wall thickening and cardiomegaly, which comprises luteolin or a derivative thereof as an active ingredient.Type: ApplicationFiled: July 19, 2012Publication date: July 10, 2014Applicants: THERAVALUES CORPORATION, THE UNIVERSITY OF TOKYOInventors: Hiroyuki Morita, Ryozo Nagai, Atsuko Nakayama, Tadashi Hashimoto
-
Patent number: 8053461Abstract: A compound or a pharmaceutically acceptable salt thereof of the present invention is represented by the following general formula (I): [wherein, R1 to R8 may have a hydrogen atom, a halogen atom, a hydroxy group, a C1-C6 alkyl group, a C2-C8 alkenyl group, a C1-C6 alkylcarbonyl group or —COOR9 (wherein R9 represents a hydrogen atom, a C1-C6 alkyl group or a C2-C8 alkenyl group) as a substituent; and X represents a sulfur atom, an oxygen atom or NR10 (wherein R10 represents a hydrogen atom, a halogen atom, a hydroxy group, a C1-C6 alkyl group, a C2-C8 alkenyl group or a C1-C6 alkoxy group)].Type: GrantFiled: November 5, 2007Date of Patent: November 8, 2011Assignee: Theravalues CorporationInventors: Noriaki Shinobu, Jun Shao, Masataka Kobayashi, Takao Mori
-
Patent number: 7824872Abstract: An objective of the present invention is to provide methods of screening for novel compounds that exhibit anticancer activity. The screening methods of the present invention comprise using serine/threonine kinase Pim-1, or partial peptides or salts thereof.Type: GrantFiled: April 5, 2004Date of Patent: November 2, 2010Assignee: Theravalues CorporationInventors: Masanobu Kobayashi, Jian Chen
-
Publication number: 20100076049Abstract: A compound or a pharmaceutically acceptable salt thereof of the present invention is represented by the following general formula (I): [wherein, R1 to R8 may have a hydrogen atom, a halogen atom, a hydroxy group, a C1-C6 alkyl group, a C2-C8 alkenyl group, a C1-C6 alkylcarbonyl group or —COOR9 (wherein R9 represents a hydrogen atom, a C1-C6 alkyl group or a C2-C8 alkenyl group) as a substituent; and X represents a sulfur atom, an oxygen atom or NR10 (wherein R10 represents a hydrogen atom, a halogen atom, a hydroxy group, a C1-C6 alkyl group, a C2-C8 alkenyl group or a C1-C6 alkoxy group)].Type: ApplicationFiled: November 5, 2007Publication date: March 25, 2010Applicant: Theravalues CorporationInventors: Noriaki Shinobu, Jun Shao, Masataka Kobayashi, Takao Mori